|17.26||+0.2900||+1.71%||Vol 3.22M||1Y Perf 278.99%|
|Jul 23rd, 2021 16:00 DELAYED|
|- -||0.09 0.52%|
|Target Price||15.75||Analyst Rating||Strong Buy 1.00|
|Potential %||-8.75||Finscreener Ranking||★+ 43.05|
|Insiders Trans % 3/6/12 mo.||-100/-100/-82||Value Ranking||★★ 47.92|
|Insiders Value % 3/6/12 mo.||-100/-100/-88||Growth Ranking||★+ 41.53|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-73||Income Ranking||— -|
|Market Cap||3.07B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||96.68||Earnings Date||5th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2021|
|Estimated EPS Next Report||-0.22|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.90M|
|Avg. Monthly Volume||3.04M|
|Avg. Quarterly Volume||3.53M|
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock closed at 17.26 per share at the end of the most recent trading day (a 1.71% change compared to the prior day closing price) with a volume of 3.23M shares and market capitalization of 3.07B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 140 people. BioCryst Pharmaceuticals Inc. CEO is Jon P. Stonehouse.
The one-year performance of BioCryst Pharmaceuticals Inc. stock is 278.99%, while year-to-date (YTD) performance is 131.68%. BCRX stock has a five-year performance of 460.39%. Its 52-week range is between 3.3 and 17.74, which gives BCRX stock a 52-week price range ratio of 96.68%
BioCryst Pharmaceuticals Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 56.59, a price-to-sale (PS) ratio of 93.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -97.50%, a ROC of -96.99% and a ROE of 589.25%. The company’s profit margin is -%, its EBITDA margin is -575.50%, and its revenue ttm is $29.18 Million , which makes it $0.16 revenue per share.
Of the last four earnings reports from BioCryst Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. BioCryst Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for BioCryst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $15.75, which is -8.75% compared to the current price. The earnings rating for BioCryst Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioCryst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioCryst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.03, ATR14 : 0.76, CCI20 : 204.56, Chaikin Money Flow : 0.16, MACD : 0.24, Money Flow Index : 46.84, ROC : 8.62, RSI : 62.98, STOCH (14,3) : 86.22, STOCH RSI : 1.00, UO : 59.85, Williams %R : -13.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioCryst Pharmaceuticals Inc. in the last 12-months were: Alane Barnes (Option Excercise at a value of $823 123), Alane Barnes (Sold 157 744 shares of value $1 627 441 ), Anthony Doyle (Buy at a value of $220 320), George B. Abercrombie (Option Excercise at a value of $30 684), George B. Abercrombie (Sold 18 667 shares of value $260 021 ), Jon P. Stonehouse (Option Excercise at a value of $557 254), Jon P. Stonehouse (Sold 134 278 shares of value $1 117 193 ), Michael L. Jones (Option Excercise at a value of $15 795), William P. Sheridan (Option Excercise at a value of $171 188), William P. Sheridan (Sold 41 250 shares of value $477 263 ), Yarlagadda S. Babu (Option Excercise at a value of $207 500)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.